Although less likely to develop ovarian cancer, black women have consistently worse survival compared with white women.
A pre-existing immune response is linked to worse survival rates compared with their white counterparts. Five genes are overexpressed in African American patients associated with the IDO immune pathway*.
African American enrolment is 19 times lower than expected for ovarian clinical trials, which causes bias towards therapy trials targeting white women.
*The IDO Pathway restricts T-cell function limiting immune reactions to cancer
No comments:
Post a Comment